Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Will Eye Primary Care Acquisitions To Complement Vytorin, Zetia

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Hassan vows not to repeat mistakes of Schering's past by relying on the cholesterol agents to carry the business for the long-term. Bayer's oral Factor Xa inhibitor is a potential acquisition candidate, depending on how the antithrombotic fares in Phase III.

You may also be interested in...



Schering-Plough Sets Acquisition Sights On Specialty Products

The company has entered the third – or “turnaround” – phase of its five-point restructuring program.

Schering-Plough Sets Acquisition Sights On Specialty Products

The company has entered the third – or “turnaround” – phase of its five-point restructuring program.

Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer

Bayer abandons primary care market in U.S. and will cut 1,800 sales positions. Schering-Plough will take over marketing of Avelox and Cipro as well as Bayer's portion of Levitra co-promotion efforts.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel